Lido Advisors LLC Buys 1,009 Shares of United Therapeutics Corporation $UTHR

Lido Advisors LLC raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 156.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,653 shares of the biotechnology company’s stock after buying an additional 1,009 shares during the quarter. Lido Advisors LLC’s holdings in United Therapeutics were worth $981,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of UTHR. Torren Management LLC acquired a new position in United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 0.8%

UTHR stock opened at $523.63 on Wednesday. The stock has a 50-day moving average price of $546.23 and a two-hundred day moving average price of $532.01. The stock has a market cap of $22.23 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $6.63 EPS. On average, analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,921,276.08. This trade represents a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 512,833 shares of company stock worth $285,561,257 in the last ninety days. 8.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

UTHR has been the subject of several research analyst reports. Royal Bank Of Canada boosted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $648.33.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Wall Street maintains a generally constructive view: 11 analysts rate UTHR a Buy and two rate it Hold, producing a consensus “Moderate Buy” rating and an average price target of $648.33. JPMorgan recently raised its target to $687, while HC Wainwright lifted its target to $660. United Therapeutics Corporation Given Average Rating of Moderate Buy by Brokerages
• Positive Sentiment: Institutional investors continued adding to positions during the second quarter. Assenagon Asset Management increased its stake by 79.2%, and Versant Capital Management nearly doubled its position. Institutions collectively own about 94.1% of UTHR’s outstanding shares.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.04 million at an average price of $530.42 on July 27. She retained 324,443 directly held shares valued at roughly $172 million, so the transaction reduced her direct position by 2.84% but does not represent an exit from the company. Insider Selling: United Therapeutics CEO Sells $5 Million of Stock
• Negative Sentiment: The CEO’s repeated recent share disposals may weigh on sentiment, particularly while UTHR trades below its 50-day and 200-day moving averages. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook.
• Negative Sentiment: United Therapeutics’ latest reported quarter showed weaker-than-expected results: earnings per share were $5.82 versus a $7.00 consensus estimate, revenue was $781.5 million versus $797.4 million expected, and revenue declined 1.6% year over year. These results remain a fundamental concern despite full-year earnings estimates of $26.65 per share.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.